InvestSMART

Prescient Therapeutics Limited (ASX: PTX) - Announcements

- Current share price for PTX : $0.068

ASX company news and announcements for Prescient Therapeutics Limited (PTX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Prescient Therapeutics Limited (PTX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Prescient Therapeutics Limited (PTX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Prescient Therapeutics Limited (PTX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$72 June 2025 Quarterly Update and Appendix 4C 30 Jul 2025 9:41AM $0.045 $0.068 risen by 51.11%
$72 Prescient announces results of SPP & Launches Placement 29 Jul 2025 9:54AM $0.045 $0.068 risen by 51.11%
$72 Trading Halt 29 Jul 2025 9:16AM $0.045 $0.068 risen by 51.11%
$72 Prescient Therapeutics - Extension of Share Purchase Plan 22 Jul 2025 9:44AM $0.046 $0.068 risen by 47.83%
$72 PTX Opens First U.S. Site for PTX-100 Phase 2a Trial 16 Jul 2025 9:08AM $0.042 $0.068 risen by 61.90%
$72 Update - Proposed issue of securities - PTX 15 Jul 2025 1:01PM $0.042 $0.068 risen by 61.90%
$72 Prescient Therapeutics Extends Share Purchase Plan 15 Jul 2025 9:18AM $0.043 $0.068 risen by 58.14%
$72 Notification of cessation of securities - PTX 14 Jul 2025 1:33PM $0.042 $0.068 risen by 61.90%
$72 Notification of cessation of securities - PTX 8 Jul 2025 12:00PM $0.042 $0.068 risen by 61.90%
$72 Prescient Share Purchase Plan Investor Presentation 4 Jul 2025 9:18AM $0.043 $0.068 risen by 58.14%
$72 Prescient Therapeutics Opens Share Purchase Plan 2 Jul 2025 9:21AM $0.041 $0.068 risen by 65.85%
$72 Share Purchase Plan Cleansing Notice 2 Jul 2025 9:08AM $0.041 $0.068 risen by 65.85%
$72 Proposed issue of securities - PTX 1 Jul 2025 9:10AM $0.044 $0.068 risen by 54.55%
$72 Prescient Therapeutics Launches Share Purchase Plan for $7m 1 Jul 2025 9:10AM $0.044 $0.068 risen by 54.55%
$72 Change of Registered Office and Principal Place of Business 2 Jun 2025 9:54AM $0.046 $0.068 risen by 47.83%
$72 PTX Updated Investor Presentation 29 May 2025 11:00AM $0.050 $0.068 risen by 36%
$72 First Patient dosed for PTX-100 Phase 2a Study 27 May 2025 9:07AM $0.046 $0.068 risen by 47.83%
$72 Prescient Therapeutics - Investor Briefing 21 May 2025 11:19AM $0.047 $0.068 risen by 44.68%
$72 Change of Director's Interest Notice 6 May 2025 1:22PM $0.047 $0.068 risen by 44.68%
$72 Change of Director's Interest Notice 2 May 2025 12:28PM $0.047 $0.068 risen by 44.68%
$72 March 2025 Quarterly Update and Appendix 4C 28 Apr 2025 10:00AM $0.049 $0.068 risen by 38.78%
$72 Prescient Therapeutics - Investor Briefing 17 Apr 2025 12:04PM $0.045 $0.068 risen by 51.11%
$72 PTX-100 receives U.S. FDA Fast Track Designation 16 Apr 2025 9:20AM $0.042 $0.068 risen by 61.90%
$72 Initial Director's Interest Notice 11 Apr 2025 9:53AM $0.041 $0.068 risen by 65.85%
$72 PTX appoints Melanie Farris as Non-Executive Director 10 Apr 2025 9:06AM $0.039 $0.068 risen by 74.36%

51 - 75 of 584 results

Page 3 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.